Navigation Links
Gloucester Pharmaceuticals Reports on Romidepsin and Erlotinib,Combination in Non-Small Cell Lung Cancer Presented at American,Association of Cancer Research Annual Meeting

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr 18, 2007 - Gloucester Pharmaceuticals, Inc., an oncology focused biopharmaceutical company, announced today that encouraging data from a preclinical study examining the combination of romidepsin and erlotinib in non-small cell lung cancer (NSCLC) cell lines derived from human cancer patients were presented at the American Association of Cancer Research Meeting annual meeting taking place in Los Angles, CA. The study was co-authored by Wei Zhang, Ph.D., Michael Peyton, Ph.D., John D. Minna, M.D., Adi F. Gazdar, M.D. and Eugene P. Frenkel, M.D., all of the Hamon Center for Therapeutic Oncology Research at University of Texas Southwestern Medical Center.

In an oral presentation entitled "Histone deacetylase inhibitor romidepsin enhances anti-tumor effect of erlotinib in non-small cell lung cancer (NSCLC) cell lines" Dr. Zhang showed data from a preclinical study designed to examine the effect of the histone deacetylase (HDAC) inhibitor romidepsin in combination with the tyrosine kinase inhibitor (TKI) erlotinib in NSCLC. In the in vitro arm of the study, 22 NSCLC cell lines were treated with either romidepsin, erlotinib or romidepsin and erlotinib together. For the in vivo arm of the study H1299 xenografts were inoculated subcutaneously into nude mice. The developing tumors were treated with either romidepsin, erlotinib or romidepsin and erlotinib together.

In her conclusions Dr. Zhang reported that romidepsin synergistically enhanced erlotinib sensitivity in wild type NSCLC cell lines by induction of profound apoptosis. This synergy was also shown in the nude mice xenografts but was not observed in epidermal growth factor (EGFR) mutant cell lines.

"The data from this study are very promising and suggest that combining romidepsin with TKIs such as erlotinib may enhance the clinical activity in the non-EGFR mutant patient population, which is thought to be approx
'"/>




Page: 1 2 3

Related medicine technology :

1. Gloucester Pharmaceuticals Reports Positive Interim Phase II Data on Romidepsin for T-Cell Lymphomas at the 2007 American Society of Clinical Oncology Annual Meeting
2. Gloucester Pharmaceuticals Receives Fast Track Designation for Romidepsin in Peripheral T-Cell Lymphoma
3. Gloucester Pharmaceuticals Announces Multiple Presentations of Preclinical Romidepsin Data at American Association of Cancer Research Annual Meeting
4. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
5. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
7. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
8. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
9. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
10. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
11. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
Post Your Comments:
(Date:7/6/2015)... 2015 Celtaxsys, Inc., a clinical stage pharmaceutical ... rare and orphan inflammatory disease indications, announced today that ... Drug Administration (FDA) to begin a Phase 2 clinical ... adult CF patients in the US. The regulatory submissions ... will be filed soon after. This groundbreaking clinical ...
(Date:7/6/2015)... SOUTH SAN FRANCISCO, Calif. , July ... ), a leading global pharmaceutical company, and Oculeve, a ... for dry eye disease, today announced that they have ... Oculeve in an all-cash transaction.  Under the terms of ... million upfront payment and commercialization milestone payments related to ...
(Date:7/6/2015)... -- China Information Technology, Inc. (the "Company" or "CNIT") ... platform, exchange, and big data solutions in ... its mobile app for Healthcare One Pass, ushering in ... devices. The Company jointly hosted the launch ceremony with ... Shenzhen News Net.   The mobile app for ...
Breaking Medicine Technology:Celtaxsys, Inc. Gains FDA Clearance for Landmark Phase 2 Trial of Anti-Inflammatory Treatment for Cystic Fibrosis (CF) 2Celtaxsys, Inc. Gains FDA Clearance for Landmark Phase 2 Trial of Anti-Inflammatory Treatment for Cystic Fibrosis (CF) 3Allergan to Acquire Oculeve Dry Eye Disease Development Programs 2Allergan to Acquire Oculeve Dry Eye Disease Development Programs 3Allergan to Acquire Oculeve Dry Eye Disease Development Programs 4CNIT Launches the Mobile App for Healthcare One Pass 2CNIT Launches the Mobile App for Healthcare One Pass 3CNIT Launches the Mobile App for Healthcare One Pass 4
... ... Anticancer Drug, HOUSTON, ... to families, workplaces and communities, and many,Houstonians are aware of ... the CHRISTUS Stehlin Foundation for,Cancer Research, a nationally recognized leader ...
Journalists and other readers should disregard the news release "Oramed,Pharmaceuticals Launches Phase 1A Trials of its Insulin Suppository",OTC:ORMP, issued earlier today. The release was transmitted...
Cached Medicine Technology:Local Research Foundation Achieves Milestone in Fight Against Cancer 2Local Research Foundation Achieves Milestone in Fight Against Cancer 3
(Date:7/7/2015)... , ... July 07, 2015 , ... ... Ellen Purdy as the company’s new Chief Financial Officer, effective July 6th, 2015. ... experience in companies ranging from a multi-billion dollar, global chemical company to early ...
(Date:7/7/2015)... Annapolis, MD (PRWEB) , ... July 07, 2015 ... ... quality and an official accrediting body as designated by the Centers for Medicare ... improved user experience and to enhance compatibility with mobile devices. , The most ...
(Date:7/7/2015)... ON (PRWEB) , ... July 07, 2015 , ... On ... is effective immediately and permits the use of gluten-free claims for gluten free oats ... prospect of expanding the Gluten-Free Certification Program (GFCP) to include gluten-free oat ...
(Date:7/7/2015)... ... July 07, 2015 , ... CareSync proudly announces today ... by the White House as a “Champion of Change” for Precision Medicine on ... the Champions of Change program recognizes Gleason and eight other extraordinary individuals who ...
(Date:7/6/2015)... ... July 06, 2015 , ... For over twenty years, Doctors ... injury victims. Throughout the company’s history the goal has been to be a ... in their recovery. And while Doctors on Liens has certainly achieved that goal, ...
Breaking Medicine News(10 mins):Health News:Office Practicum Announces new CFO 2Health News:RadSite Releases Mobile-friendly Website for Enhanced User Experience 2Health News:RadSite Releases Mobile-friendly Website for Enhanced User Experience 3Health News:Holy Crap Plus Gluten Free Oats Is The First Product With Oats In Canada To Carry The Gluten-Free Certification Program Trademark 2Health News:Holy Crap Plus Gluten Free Oats Is The First Product With Oats In Canada To Carry The Gluten-Free Certification Program Trademark 3Health News:Holy Crap Plus Gluten Free Oats Is The First Product With Oats In Canada To Carry The Gluten-Free Certification Program Trademark 4Health News:White House names Champions of Change for Precision Medicine: CareSync COO Recognized 2Health News:White House names Champions of Change for Precision Medicine: CareSync COO Recognized 3Health News:Doctors on Liens Adds Transportation to Its Ever-Expanding Network 2Health News:Doctors on Liens Adds Transportation to Its Ever-Expanding Network 3
... City Hotel and Casino will host the 3rd ... ReceptionATLANTIC CITY, N.J., Feb. 17 The American ... are teaming up on Wednesday, February 25, 2009 ... Blood Donor Campaign awards reception.(Logo: http://www.newscom.com/cgi-bin/prnh/20090217/DC71647LOGO ...
... Six studies published in the past year by a Cornell ... -- as well as daily helpings of other fruits and ... one of his recent papers, published in the Journal ... Cornell associate professor of food science and a member of ...
... (Feb. 17, 2009) A research project at Rice ... long-standing medical mystery that may link cardiovascular disease, osteoporosis and ... thank the rat. , The recent paper in Artery ... team reports they have found that common rats with a ...
... TORONTO, Feb. 17 /PRNewswire/ - Sentinelle Medical Inc., ... software and Siemens Healthcare today announced an OEM ... agreement, Siemens will sell the "Sentinelle Vanguard for ... Espree, MAGNETOM(R) Avanto and MAGNETOM(R) Symphony, A Tim(TM) ...
... by wartime conditions, researchers say , , TUESDAY, Feb. 17 ... can be exacerbated by combat conditions in Iraq and ... being evacuated for treatment, a new report finds. , ... responsible for poor morale and combat ineffectiveness, the researchers ...
... from The University of Nottingham are taking to the streets ... are nearly twice the national average. , Reducing high levels ... which ranks third highest in the country after Corby and ... Control Studies and Professor in Health Policy and Promotion at ...
Cached Medicine News:Health News:The American Red Cross Recognizes Atlantic City Casinos 2Health News:In flurry of studies, researcher details role of apples in inhibiting breast cancer 2Health News:Mutant rats offer clues to medical mystery 2Health News:Mutant rats offer clues to medical mystery 3Health News:Sentinelle Medical Enters OEM Distribution Agreement with Siemens AG 2Health News:Sentinelle Medical Enters OEM Distribution Agreement with Siemens AG 3Health News:Skin Woes Take Toll on U.S. Combat Troops 2Health News:Skin Woes Take Toll on U.S. Combat Troops 3Health News:Investigating a community where smoking rates are double the national average 2
... Split Splint reduces PIP joint or DIP joint ... to put on. Soft gel-lining cushions injured fingers ... begin earlier for faster, more successful therapy results. ... and at night to maintain gains in motion. ...
... FoamWrap Final Flexion Wraps restore full PIP ... or when lost due to arthritic changes. ... foam-lined material hugs the finger to prevent ... restore motion. One size. Sold in packages ...
One splint does it all....
... of minor knee pain like arthritis, tendonitis ... with the motion of the knee, applying ... tendon and assisting in the relief of ... with high density foam padding molds itself ...
Medicine Products: